Argenica Therapeutics Ltd (AGN) - Net Assets
Based on the latest financial reports, Argenica Therapeutics Ltd (AGN) has net assets worth AU$3.44 Million AUD (≈ $2.44 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$5.20 Million ≈ $3.68 Million USD) and total liabilities (AU$1.76 Million ≈ $1.24 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Argenica Therapeutics Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$3.44 Million |
| % of Total Assets | 66.21% |
| Annual Growth Rate | 230.18% |
| 5-Year Change | 5.7% |
| 10-Year Change | N/A |
| Growth Volatility | 14841.97 |
Argenica Therapeutics Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Argenica Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Argenica Therapeutics Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Argenica Therapeutics Ltd (2019–2024)
The table below shows the annual net assets of Argenica Therapeutics Ltd from 2019 to 2024. For live valuation and market cap data, see AGN market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | AU$7.24 Million ≈ $5.12 Million |
-48.12% |
| 2023-12-31 | AU$13.95 Million ≈ $9.87 Million |
+81.97% |
| 2022-12-31 | AU$7.67 Million ≈ $5.42 Million |
-7.72% |
| 2021-12-31 | AU$8.31 Million ≈ $5.88 Million |
+21.33% |
| 2020-12-31 | AU$6.85 Million ≈ $4.84 Million |
+37116.65% |
| 2019-12-31 | AU$18.40K ≈ $13.02K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Argenica Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2234979700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$29.63 Million | 409.41% |
| Other Comprehensive Income | AU$340.52K | 4.71% |
| Total Equity | AU$7.24 Million | 100.00% |
Argenica Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Argenica Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RPCG Public Company Limited
BK:RPC
|
$15.45 Million |
|
Janfusun Fancyworld
TWO:5701
|
$15.45 Million |
|
Mega Polietilen Kopuk Sanayi ve Ticaret AS
IS:MEGAP
|
$15.46 Million |
|
Middle Island Resources Ltd
AU:MDI
|
$15.46 Million |
|
MyTech Group Bhd
KLSE:7692
|
$15.45 Million |
|
Cubex Tubings Limited
NSE:CUBEXTUB
|
$15.45 Million |
|
Immo Moury SICAF Immobiliere Publique de Droit Belge
BR:IMMOU
|
$15.43 Million |
|
Torrent Capital Ltd
V:TORR
|
$15.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Argenica Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,950,835 to 7,237,271, a change of -6,713,564 (-48.1%).
- Net loss of 7,170,347 reduced equity.
- New share issuances of 346,897 increased equity.
- Other comprehensive income decreased equity by 867,626.
- Other factors increased equity by 977,512.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-7.17 Million | -99.08% |
| Share Issuances | AU$346.90K | +4.79% |
| Other Comprehensive Income | AU$-867.63K | -11.99% |
| Other Changes | AU$977.51K | +13.51% |
| Total Change | AU$- | -48.12% |
Book Value vs Market Value Analysis
This analysis compares Argenica Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.00x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 676.16x to 3.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | AU$0.00 | AU$0.17 | x |
| 2020-12-31 | AU$0.09 | AU$0.17 | x |
| 2021-12-31 | AU$0.11 | AU$0.17 | x |
| 2022-12-31 | AU$0.09 | AU$0.17 | x |
| 2023-12-31 | AU$0.13 | AU$0.17 | x |
| 2024-12-31 | AU$0.06 | AU$0.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Argenica Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -99.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -223.11%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.53x
- Recent ROE (-99.08%) is above the historical average (-391.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -2084.05% | -153361.20% | 0.00x | 20.53x | AU$-385.24K |
| 2020 | -15.04% | -514750.50% | 0.00x | 1.06x | AU$-1.71 Million |
| 2021 | -49.24% | -163630.08% | 0.00x | 1.09x | AU$-4.92 Million |
| 2022 | -62.81% | -275.16% | 0.18x | 1.24x | AU$-5.58 Million |
| 2023 | -39.28% | -210.92% | 0.16x | 1.17x | AU$-6.87 Million |
| 2024 | -99.08% | -223.11% | 0.29x | 1.53x | AU$-7.89 Million |
Industry Comparison
This section compares Argenica Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $9,350,708
- Average return on equity (ROE) among peers: -74.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Argenica Therapeutics Ltd (AGN) | AU$3.44 Million | -2084.05% | 0.51x | $15.45 Million |
| Adalta Ltd (1AD) | $3.70 Million | -162.25% | 0.87x | $6.50 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $-1.33 Million | 0.00% | 0.00x | $20.04 Million |
| ACRUX Ltd (ACR) | $12.85 Million | -73.71% | 0.44x | $3.20 Million |
| Actinogen Medical Ltd (ACW) | $21.74 Million | -43.69% | 0.07x | $105.70 Million |
| Arovella Therapeutics Ltd (ALA) | $11.03 Million | -40.87% | 0.23x | $58.08 Million |
| Anatara Lifesciences Ltd (ANR) | $924.54K | -218.83% | 0.54x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $20.73 Million | -6.40% | 0.01x | $76.95 Million |
| Amplia Therapeutics Ltd (ATX) | $11.23 Million | -30.16% | 0.02x | $50.82 Million |
| Avecho Biotechnology Ltd (AVE) | $3.27 Million | -95.48% | 0.53x | $28.59 Million |
About Argenica Therapeutics Ltd
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Aus… Read more